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Abstract
Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an
uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with
metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth
extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should
be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed
based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ
onset.
Based on the different pharmacological activity of denosumab and nitrogen-containing bisphosphonates, it is likely
that the MRONJ risk profile of patients with osteoporosis could somewhat vary.
We hypothesize the chance to maximize the pharmacokinetic of denosumab 60 mg (Prolia®) and identify a time
interval in which invasive oral treatments can ideally take place without restrictions in patients with metabolic bone
fragility,
We propose that dental surgery (e.g. tooth extraction) may be safely performed without additional intra or peri-
operative procedures in osteoporosis patients using denosumab provided that careful case selection, adequate
communication among specialists, planning of a delayed dosing window (1-month deferral) and rigorous
postoperative follow-up are granted.
Keywords: Medication-related osteonecrosis of the jaw, MRONJ, Denosumab, osteoporosis, Oral surgery, tooth
extraction
Medication-Related OsteoNecrosis of the Jaw (MRONJ)
is associated with the use of bone modifying agents
(BMAs) and, less commonly, anti-angiogenics [1, 2].
MRONJ is rarely observed in individuals with osteo-
metabolic disorders (prevalence ranges between 0 and
0.4%), whereas it develops more commonly in metastatic
cancer patients (0.2–6.7% prevalence) [3]. Although the
etiopathogenesis of MRONJ remains unclear, the ex-
treme inhibition of bone turnover together with local in-
fection seem to represent the mechanisms of MRONJ
development in patients receiving BMAs.
The length and cumulative dosage of antiresorptive
therapy are associated with an increased risk of MRONJ
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development [4]. Furthermore, dental/periodontal infec-
tion and dentoalveolar surgery (e.g. dental extractions)
have also been associated with MRONJ development [5].
As dental diseases are very prevalent and dental ex-
tractions are routinely and regularly performed in a large
number of patients, risk-reduction strategies have been
investigated with a view to minimise the risk of MRONJ
development in individual who use BMAs and are in
need of dental extractions.
The temporary discontinuation (i.e. drug holiday) of
nitrogen-containing bisphosphonates (N-BPs) before
dental surgery has become quite common in the clinical
practice to minimise the risk of MRONJ. However, the
effectiveness of a drug holiday not only has not been
proved yet, but also lack a clear rationale based on the
pharmacokinetics/pharmacodynamics of N-BPs. For
these reasons, N-BPs discontinuation is not beneficial, at
present [2, 3].
In the past years, the routine use of simple and surgi-
cal extraction of non-restorable teeth to eliminate den-
tal/periodontal infections in patients with skeletal
fragility undergoing N-BPs treatment was based on an
individual risk-stratification [2, 6]. For example, alveolo-
plasty and primary wound closure have been proved suc-
cessful and protecting in patients at increased risk of
MRONJ [5].
However, some studies on alveoloplasty and primary
wound closure were based on a one-fits-all approach,
and did not attempt to identify and risk-stratify patients
in groups at higher or lower risk of post-extraction
MRONJ development [7].
Assessment of individual MRONJ risk profile (high
risk vs low risk) becomes critical to select the appropri-
ate dental treatment and defend patients from unneces-
sary (overtreatment) or deficient (undertreatment)
interventions.
The cumulative risk of MRONJ in patients receiving
BMAs for metabolic bone fragility increases with the
time and reflects the rate of bone turnover suppression
that largely depends on the dosage regimen and the dur-
ation of treatment; that risk is at least comparable for N-
BPs and denosumab (DNB)(Fig. 1).
While cumulative dosage plays a key role in the indi-
vidual risk assessment of MRONJ in patients receiving
N-BPs irrespective of the route of administration, this
could not be true for patients receiving low-dose DNB
(Prolia®). In fact, DNB does not bind to hydroxyapatite
and incorporate into bone; thus, bone turnover recovers
rapidly after drug suspension [8].
.As a result, interruption of DNB therapy before dental
surgery is not advisable as it would expose osteoporosis
patients to a rebound fracture risk [9].
.
Here we propose an alternative risk-reduction strategy
for the osteoporosis patients receiving denosumab (Pro-
lia®) that is based on the assessment of the patient’s indi-
vidual risk associated with the pharmacokinetic/
pharmacodynamic characteristics of the given
medication.
The pharmacokinetics and pharmacodynamics of
denosumab have been extensively investigated in mul-
tiple clinical studies [10–14]. Denosumab after a 60 mg
subcutaneous dose was slowly absorbed, with peak
serum concentration values generally reached within 4
weeks postdose. The serum concentration-time profile
declined over a period of 4–5 months after the Cmax.
The decline is biphasic, with an initial phase during
which serum concentrations declined approximately
linearly from peak followed by a more rapid terminal
phase, with a serum concentrations mean half-life of ap-
proximately 25–30 days. At 24 months denosumab levels
was similar to baseline level [10–13]. In addition, there
has been no evidence of time-dependent pharmacokinet-
ics after repeated dosing with the denosumab adminis-
tered every 6 months (from 4months to 4 years of
exposure) [10, 12]. The reversibility of the pharmacody-
namic effects (based on serum bone turnover markers)
was observed at the end of the dosing interval [10, 14].
The mean serum CTX concentration decreased over
80% within 5 days after dosing; CTX starts to rise slowly
from 4months and at 6 months from the dose is up 10%
compared to nadir [14].
The clinical relevance of body weight, race and age
effects on pharmacokinetic parameters is probably
Fig. 1 MRONJ risk profile of patients with metabolic bone fragility receiving Antiresorptive medications (BMAs)
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limited, since a substantial overlap, as supported by
pharmacokinetic and pharmacodynamic analysis
where the covariate effect had a negligible impact
[12, 13].
.
Accordingly, DNB pharmacokinetics suggest the
presence of a window of opportunity between post-
dose month 5 and 7, where recovery of bone turn-
over is initiated and dental extractions may be per-
formed with a reduced risk of MRONJ development
(Fig. 2).
The recently acquired information that more than 7-
month interval between 2 consecutive denosumab injec-
tions is likely to negatively impact on bone mineral
density scores of osteoporosis patients during the off-
treatment period, makes it practicable a 1-month delay
of the subsequent dose of Prolia® to achieve mucosal
healing following dental extraction [15, 16].
In order to adopt this strategy and benefit from this
window of opportunity, dental practitioners should:
1. identify patients where dental surgery can be safely
deferred to the 5th month following the last DNB
dose;
2. communicate with the bone specialist (drug
prescriber) and discuss the feasibility of delaying the
following DNB dose by 1 month;
3. provide patients with exhaustive information about
the possible risk and benefit of the planned
procedure;
4. perform dental surgery based on routine dental care
and strictly follow-up the healing process;
5. promptly communicate the progress of healing to
the bone specialist, who will schedule the next dose
of DNB.
In conclusion, we specul9ate that dental surgery may
be safely performed without additional intra or peri-
operative procedures in osteoporosis patients using DNB
provided that careful case selection, adequate communi-
cation between health care providers is ensured and a 1-
month deferral in the next DNB dose is feasible. Well-
designed clinical trials are required to prove that this ap-
proach is effective while keeping on a low risk of
MRONJ development.
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